INTRODUCTION
Despite its tremendous benefits, highly active antiretroviral therapy (HAART) is not able to eradicate human immunodeficiency virus (HIV) from treated patients (1) . In this scenario, the continuously increasing number of viral strains that are resistant to therapy, as well as the adverse drug side effects that are frequently associated with long-term treatment, pose a serious threat to the current treatment success and require the development of new anti-HIV type 1 (HIV-1) compounds (2) . In particular, the recent therapeutic success of T-20, a peptide inhibiting viral entry, has highlighted the general potential of HIV-1 entry/fusion inhibitors to complement current highly active antiretroviral therapy. While T-20 is an example of successful rational drug design, other compounds such as ALX 40-4C, a nonpeptide molecule inhibiting HIV-1 entry by targeting the HIV-1 coreceptor CXCR4, demonstrate the limitations of this approach: ALX 40-4C was initially designed to inhibit HIV-1 Tat activity, but in vitro experiments revealed that its mode of action was the inhibition of viral entry (3, 4) . Despite the tremendous advances rational drug design has brought to the field, such examples demonstrate the particular value of cell-based highthroughput screening (HTS) assays. For this purpose, a variety of cell lines and reporter assays that are suitable for HTS to various degrees have been established (5) (6) (7) (8) (9) . Suitability is mostly defined by the costs of the actual screening and the time required for the assay. To justify the screening of an industrial-size compound library, which can hold several million compounds, the screening costs per compound need to be minimized. An ideal reporter cell line to screen for inhibitors of HIV-1 replication thus needs to fulfill several requirements: (i) the reporter cell line should be an immortalized T-cell line expressing both HIV-1 coreceptors, CXCR4 and CCR5, and (ii) the reporter cell line should provide a stable and quantifiable marker for HIV-1 expression, such as secreted alkaline phosphatase (SEAP), luciferase, or enhanced green fluorescent protein (EGFP) to avoid the costly and timeconsuming direct detection and quantification of viral gene products [e.g., HIV-1 p24 enzyme-linked immunosorbent assay (ELISA) and reverse transcription assay]. Two reporter cell lines, MOCHA (10) and CEM. NKR-CCR5-Luc (11) , which meet these criteria were recently published. The cell lines use SEAP or luciferase, respectively, under the control of an HIV-1 long terminal repeat (LTR) as the indicator of HIV-1 expression. However, during assay analysis, these cell lines still require time-consuming or relatively costly manipulation of the cell culture (cell lysis, supernatant
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transfer, and the addition of chemicals) to obtain the final readout.
Here we demonstrate that, based on a stably integrated LTR-EGFP reporter construct, HIV-1 expression in the JTRG-R5 reporter cell line can be directly detected and quantified in cell culture without additional manipulation. This not only significantly reduces the costs of any HTS effort but also provides the opportunity for the direct kinetic analysis of drug effects on HIV-1 expression over an extended time period. In addition, the cell line allows for single-cell analysis using flow cytometry. Using EGFP as a direct marker of HIV-1 infection, follow-up experiments that define the characteristics of an identified lead compound can then be performed with great convenience. If compound availability is low, cells from wells with positive drug hits identified during a drug screen can be removed from the plate and directly subjected to flow cytometry to account for potential cytotoxic or apoptotic effects of the tested compound. We demonstrate that JLTRG-R5 cells can be used in a 384-well plate-based format and quantitatively reflect previous findings obtained from peripheral blood mononuclear cell (PBMC) cultures. Thus, the cell line improves existing methodologies to identify novel anti-HIV-1 compounds.
MATERIALS AND METHODS

Cell Culture and Reagents
The reporter T-cell lines JLTRG and JLTRG-R5 were maintained at an average cell density of 0.5 × 10 6 cells/mL in RPMI 1640 (Mediatech, Herndon, VA, USA) supplemented with 2 mM l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% heat-inactivated fetal bovine serum (FBS; HyClone, Logan, UT, USA) (12) . The cell lines are identical with respect to CD4 and CXCR4 expression, but only JLTRG-R5 cells express CCR5. We found that CCR5 expression on JLTRG-R5 cells was relatively stable in long-term culture. Over a two-year culture period, only 30% of the cells lost CCR5 expression. Complete CCR5 expression on a population basis can be easily reestablished by enriching CCR5-positive cells using anti-CCR5 antibody-coated magnetic beads (Dynal Biotech, Lake Success, NY, USA) or by fluorescenceactivated cell sorting techniques. Prior to the infection experiments, the cells were split to 1 × 10 5 cells/mL and then grown to a density of 5 × 10 5 cells/mL to assure optimal susceptibility to HIV-1 infection. JC53BL-13 cells (TZM-BL) were cultured and infected as previously described (13) . Briefly, the cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Mediatech) supplemented with 2 mM l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% heatinactivated FBS.
PBMCs used to generate infectious viral supernatants were isolated from the blood of healthy donors by FicollPaque™ density gradient centrifugation (Amersham Biosciences, Uppsala, Sweden) and were cultured in RPMI 1640 supplemented with 10% heatinactivated FBS, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. PBMCs were initially PHA/interleukin-2 stimulated and infected with the various HIV-1 patient isolates and HIV-1 clones 4 days following stimulation. All antibodies were purchased from BD Pharmingen (San Diego, CA, USA). PHA-L was obtained from Sigma (St. Louis, MO, USA), and IL-2 was purchased from Biosource International (Camarillo, CA, USA).
Generation of Infectious Viral Supernatants and Patient Sera
The In all cases, informed consent was obtained from the respective patients that allowed usage of the samples for research purposes. HIV-1 NL4-3, HIV-1 SF162, and HIV-1 BAL were obtained from the National Institutes of Health (NIH; Bethesda, MD, USA) AIDS Research and Reference Reagent Program (www.aidsreagent.org). All primary patient isolates were propagated in PBMC cultures using phenol red-free RPMI 1640 supplemented with 5% heat-inactivated FBS, 2 mM l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 50 U/mL IL-2. Supernatants were harvested continuously between days 4 and 7 following infection and adjusted for the experiments by either p24 concentration or infectious units as determined on JLTRG-R5 cells.
Flow Cytometric Analysis
Flow cytometric analysis was performed using a FACScan™ and CellQuest™ software or an LSR II flow cytometer and FACSDiva™ software (all from BD Biosciences, San Jose, (14) .
384-Well Plate-Based Assays
All plate-based experiments were performed in 384-well optical bottom black wall plates (Nalge Nunc International, Rochester, NY, USA) and designed to obtain a final cell density of 1 × 10 6 cells/mL in a final volume of 90 μL phenol red-free RPMI 1640 per well. This optimal number was obtained by titrating JLTRG-R5 cells over a range of cell numbers per well (1 × 10 3 to 1 × 10 6 cell/well) and infecting the cells with HIV-1 NL4-3, followed by plate-based fluorometry 3-6 days postinfection. The phenol red-free RPMI 1640 used in all experiments was supplemented with 2 mM l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2% heat-inactivated FBS. Infections were performed in the absence or presence of 4 μg/mL diethylaminoethyl (DEAE)-dextran (molecular weight: 5000), which on average resulted in a 20% increase in the obtained signal. The absence or presence of DEAE-dextran did not alter the quantitative ability of patient sera, TAK-779, or T-20 to neutralize HIV-1 infection. Analysis was performed using a Synergy™ HT Multi-Detection Microplate Reader (Bio-Tek Instruments, Winooski, VT, USA), equipped with the following filter set: excitation, 488/20 nm; emission, 525/20 nm.
To determine the Z′-factor, JLTRG-R5 cells were adjusted to a cell density of 2 × 10 6 cells/mL in phenol red-free RPMI 1640 supplemented with 2% FBS, of which 50 μL were loaded per well. The addition of 50 μL of infectious viral cell culture supernatants per well [equal to a multiplicity of infection (MOI) of 0.1] or 50 μL of RPMI supplemented with 2% FBS resulted in a final cell density of 100,000 cells/ well in a total volume of 100 μL (or 1 × 10 6 cells/mL). 
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Inhibition of Infection by Antiretroviral Compounds and Neutralizing Antibodies
To determine the inhibitory concentration, 50% (IC 50 ) of the HIV-1 reverse transcriptase inhibitor AZT, JLTRG-R5 cells were adjusted to a cell density of 2.5 × 10 6 cells/mL, and 40 μL of this cell suspension were loaded into each well. The drug was then added at the various concentrations indicated in a volume of 10 μL and the cultures were infected with 50 μL of the respective viral supernatants, adjusted to give an MOI of 0.1. The 384-well plates were monitored for EGFP expression every 24 h for a total of 96 h.
The IC 50 of the neutralizing capacity of the patient sera samples (UAB CFAR Repository) was determined by the addition of 0.01 to 10 μL of the various patient sera and sera from a noninfected patient, adjusted to a total volume of 10 μL using phenol red-free RPMI, to 50 µL of the viral supernatants. Following 1 h preincubation, the sera/virus supernatant samples were added to JLTRG-R5 cells, which were loaded into the plate in 40 μL at a cell density of 2.5 × 10 6 cells/mL. To adjust for a possible influence of the patient serum on the fluorescent signal of the samples, we loaded wells with cells and the various amounts of patient samples but added 50 μL RPMI. The cultures were then monitored for EGFP expression every 24 h for a total of 96 h.
RESULTS
Establishment of JLTRG-R5 Cells
Most T-cell lines, including Jurkat cells, exclusively express CXCR4, limiting the permissiveness of these cells to infection with T-cell-tropic or dual-tropic virus clones/isolates, such as HIV-1 NL4-3 or HIV-1 WEAU, respectively (13) . Because most viruses isolated from patients use the CCR5 coreceptor, a useful reporter cell line for the discovery of HIV-1 antiretroviral compounds and neutralizing antibodies should express CCR5. To develop a reporter cell line that would allow for HTS for X4, X4/R5, and R5 HIV-1 viruses, we established a naturally CCR5-expressing JLTRG cell clone, a reporter cell line that we have previously established in our laboratory (12) . CCR5 expression levels in these cells are similar to CCR5 expression levels seen in PBMCs, but lower than in the fibroblast-based reporter cell line JC53, which is extremely susceptible to HIV-1 infection with R5 viruses (data not shown). Briefly, Jurkat cells had been stably transfected with an LTR-EGFP reporter construct and cloned, and a cell line was selected that expressed minimal levels of basal EGFP in an uninfected state, but responded to HIV-1 infection with extremely high levels of EGFP fluorescence. Clones were screened for high susceptibility to HIV-1 infection with both HIV-1 X4 and HIV-1 R5 strains. The cell line with the most desirable phenotype was named JLTRG-R5 and was chosen for further characterization. The data presented in Figure 1A show that JLTRG-R5 express high levels of CD4, CXCR4, and CCR5. JLTRG-R5 expressed similar levels of CD4 and CXCR4 relative to JLTRG (data not shown).
When infected with HIV-1 NL4-3 or HIV-1 BAL, two prototypic X4 or R5 strains, both cell lines became infected to a similar extent with the CXCR4-tropic HIV-1 NL4-3 as determined by flow cytometry. However, only JLTRG-R5 cells were susceptible to infection with the CCR5-tropic HIV-1 BAL, a result of the exclusive and distinct expression of CCR5 in JLTRG-R5 cells. The cells were infected at a low MOI of 0.01 to avoid syncytia formation that would bias flow cytometric analysis ( Figure 1B) .
We compared the relative susceptibility of JLTRG-R5 cells to infection with X4 and R5 HIV-1 to that of the established HeLa-derived indicator cell line JC53 (TZM-BL) (15), which is highly susceptible to both T-cell-tropic and macrophage-tropic HIV-1. As depicted in Figure  1C , two isogenic viruses derived from NL4-3, but encoding patient-derived X4 and R5 env genes, respectively, were titrated on both cell lines. The dose-response of reporter gene expression (luciferase activity for JC53 and EGFP-positive JLTRG-R5 cells in flow cytometry) induced by the respective X4 versus R5 HIV-1 infection was nearly identical in the JLTRG-R5 cell line and was slightly biased against R5 virus in JC53 cells. JLTRG-R5 cells were slightly less sensitive to infection; however, because the cells had been designed for HTS assays and not to determine viral fitness, this poses no actual shortcoming with respect to the intended purpose. Furthermore, Figure  1D demonstrates that fluorescence microscopy is a convenient method to observe the level of HIV-1 infection in JLTRG-R5 cells and can be used to determine the optimal time point to perform assay analysis.
Susceptibility of JLTRG-R5 Cells to Infection with Various HIV-1 Isolates
In addition to being utilized as a reporter cell line optimized for highthroughput drug screening, JLTRG-R5 cells could be used in verification assays if they can be efficiently infected by a selection of divergent HIV-1 strains. To test this possibility, JLTRG-R5 cells were infected with a We found that all strains tested were capable of efficiently infecting JLTRG-R5 cells, and the resulting fluorescent signals ranged between 6-and 20-fold over control cells as measured using a plate-based 384-well format. The results indicate that JLTRG-R5 cells express sufficient levels of functional HIV-1 receptors to allow for infection with a wide array of HIV-1 primary isolates, making them a useful tool for drug verification.
Characteristics of HIV-1 Replication in JLTRG-R5 Cells in the Presence of Reverse Transcriptase and Protease Inhibitors
To test whether JLTRG-R5 cells can be used to screen for various types of HIV-1 inhibitors and would reflect findings in PBMCs, we tested the ability of the established HIV-1 reverse transcriptase inhibitor 3TC and of the HIV-1 protease inhibitor indinavir to inhibit HIV-1 replication. For this purpose, we titrated all drugs over a wide concentration range onto JLTRG-R5 cells and then infected the cells with either HIV-1 NL4-3 or HIV-1 BAL. Infection was performed at a relatively low MOI (0.01) to avoid syncytia formation that could not be quantitatively accounted for during flow cytometric analysis. Three days postinfection, the level of infection was determined by flow cytometry using EGFP expression as a readout. The IC 50 for 3TC was determined as 0.03 μM, which reflects previous findings using HIV-1-infected PBMCs, for which the IC 50 was determined to be 0.07 μM (16) . For indinavir, the IC 50 was determined to be 0.003 μM (IC 95 = 0.1 μM), which also closely corresponds to previously reported concentrations for HIV-1 inhibition on PBMCs (IC 95 = 0.1 μM; Table 1 ) (17) . Single-cell analysis by flow cytometry in this case allowed us to directly determine the level of baseline infection (Figure 3 , dashed line) and of the ongoing viral replication during the experimental time frame.
Optimization of JLTRG-R5 Cells for Use in a 384-Well Format
For HTS to be effective, the system must produce results in an efficient platform such as a 384-well plate. We initially optimized the optimal cell density per well in this format, which we found to be 1 × 10 5 cells/well. To determine whether JLTRG-R5 cells could be used for HTS, we performed a Z′-test. The Z′-factor is a statistic value designed to reflect the dynamic range of the assay as well as the variation associated with the signal measurements. Because the Z′-factor is dimensionless, it can be used to compare similar assays (18) . The equation and the interpretation of possible Z-values are summarized in Equation 1. To determine the Z′-factor, the assay was run in a 384-well plate, but only 96 of the 384 wells were used. Each plate had 48 negative control wells and 48 HIV-1-infected wells, arranged in an alternating pattern. Both the HIV-1 NL43-infected positive wells and the negative control wells were treated with 0.1 μL dimethyl sulfoxide (DMSO), a typical carrier substance used during drug screens. The plates were analyzed for EGFP expression every 24 h for a total of 120 h. Maximal levels of fluorescence in the infected wells for both viruses were achieved after 96 h. At this time point, the Z′-factor for the infectivity assay was determined as 0.78, characterizing the assay as very robust in this HTS assay format ( Figure  4 ). Infectivity assays can be performed in the presence or absence of agents such as DEAE-dextran that assist infection efficiency by neutralizing cell 
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because no HIV-1-specific EGFP signal is present at this time. A counterscreen for compound cytotoxicity can be performed using cell lines that have been retrovirally transduced with EGFP under the control of a constitutively expressing promoter. A particularly interesting promoter for the generation of such cell lines is the murine stem cell virus (MSCV) promoter. In our hands, transduction of Jurkat cells with an MSCV-EGFP vector results in a 10-fold induction of EGFP expression above background, and the promoter remains unresponsive to stimulation with activating agents such as phorbol 12-myristate13-acetate (PMA; data not shown). However, alternatively established methods such as the addition of alamarBlue™ (Biosource International) to the wells allow for the direct detection of potential cytotoxicities.
Determination of HIV-1 Entry Inhibitor Effects Using JLTRG-R5 Cells in a 384-Well Plate Format
To provide proof that JLTRG-R5 cells can be used in the HTS-relevant 384-well format to identify novel HIV entry inhibitors, we quantified the ability of the established HIV-1 entry inhibitor T-20 and the CCR5 inhibitor TAK-779 to block entry of an X4 (NL4-3) and an R5 virus (BAL) in this assay format ( Figure 5A ). T-20 is a 36-amino acid peptide corresponding to sequences in the HR-2 domain of gp41 (HXB2 is the reference strain for this sequence). T-20 inhibits HIV-1 entry into cells presumably by binding to HR-1 and preventing the molecular interactions between HR-1 and HR-2 that lead to fusion (19) . NL4-3(DIV) contains a naturally occurring variation at position 36 (Asp) from the more commonly observed Gly (reference compendium). Changes at position 36 (e.g., Gly to Asp) such as those seen in NL4-3(GIV) have been associated with increased susceptibility to T-20 in clinical trials (15) . T-20 inhibited NL4-3(DIV), the original T-20-resistant clone, and NL4-3(GIV) and BAL infections at an IC 50 of 0.1, 0.006, and 0.005 μg/mL, respectively. These IC 50 s are consistent with previously published reports (20) . TAK-779, a nonpeptide CCR5 antagonist, was efficient at inhibiting HIV-1 BAL infection (R5) but not HIV-1 NL4-3 infection (X4), as expected (21) . The IC 50 for TAK-779 with respect to HIV-1 BAL inhibition was determined to be 0.005 μM, again in agreement with previously published data for PBMCs (Table 1) (21) . These data suggest that JLTRG-R5 cells allow for the direct identification of protease, reverse transcriptase, integrase, Tat, and entry/fusion inhibitors, as well as neutralizing antibodies, in a 384-well plate-based format. For the screening of all these inhibitors except for the identification of protease inhibitors, which requires multiple rounds of infection, pseudotyped viruses can be used with comparable efficiency (data not shown).
Determination of the Neutralizing Capacity of Anti-HIV-1 Antibodies
The idea of providing HIV-1 protection through the application or generation of efficiently neutralizing anti-HIV-1 antibodies has a long tradition. To investigate whether JLTRG-R5 cells could also be used to determine the capacity of anti-HIV-1 antibodies to neutralize HIV-1, we titrated serum from HIV-1-infected patients that had been previously demonstrated to have neutralizing capacity on JLTRG-R5 cells and then infected the cells with either HIV-1 NL4-3 or HIV-1 BAL. Again, the experiments were performed in 384-well plates to test whether JLTRG-R5 cells would provide a suitable tool to also screen for such antibodies. For this purpose, we pretreated HIV-1 NL4-3 or BAL supernatants for 1 h with various concentrations of serum from five HIV-1-infected patients (0.01-10 μL) and then transferred the supernatants to the JLTRG-R5 cultures. As positive controls, JLTRG-R5 cells were infected with viral supernatants that had been treated with serum from a healthy donor ( Figure 5 , B and C). Using the established cell line JC53, the sera KIMA, SMST, SHRO, and SPKE had been previously shown to be highly neutralizing, whereas YOAL showed only low reactivity (13) . These results could be reproduced exactly using JLTRG-R5 cells, demonstrating the feasibility of JLTRG-R5 cells to be used in assays that characterize the ability of patient sera to neutralize HIV-1 infection.
DISCUSSION
Due to the inherent mutagenic nature of HIV-1 resulting in the rapid acquisition of HIV-1 mutations conferring resistance, there is overwhelming pressure for the development of new pharmaceutical HIV-1 inhibitors in order to maintain the current success of HAART. To this end, here we introduce a T-cell-based reporter system designed for the identification of novel HIV-1 inhibitors, suitable for HTS in a platebased 384-well format. In addition, we demonstrate that the assay can be utilized to quantify the neutralizing capacity of anti-HIV-1 antibodies, thus providing a powerful tool to assist HIV-1 vaccine research.
Because fluorescent proteins can be directly detected and quantified in cell culture without any further manipulation during the assay quantification step, they provide an ideal tool to establish HTS assays. However, generally the achievable levels of EGFP expression in reporter assays described to date are too low to produce a sufficiently high EGFP reporter plasmid, any assay using JLTRG-R5 cells requires no manipulation during assay preparation (e.g., transfection of reporter plasmids) or assay analysis. The usage of EGFP as a direct and quantitative marker of HIV-1 expression permits the continuous realtime observation of the influence of putative HIV-1-inhibiting compounds on HIV-1 replication over an extended period of time, allowing us to study not only the cumulative outcome but also to observe potential differences in the inhibitory onset kinetics of various test compounds (22) . In addition, in contrast to infectivity assays that do not use EGFP as a readout, JLTRG-R5 cells can be utilized for the direct investigation of the underlying mechanism at the single-cell level using flow cytometric analysis. This feature previously had been established in CEM-GFP cells, but because these cells do not express CCR5, they are not susceptible to infection with R5 viruses and provide a poor screening tool for HIV-1 entry inhibitors (23) . In addition, in our hands, CEM-GFP cells have a high, constitutive EGFP background (one log-shift in flow cytometric analysis) when compared with the parental CEM cells, thereby significantly decreasing the dynamic range following HIV-1 infection. In fact, the strict correlation of EGFP fluorescence and HIV-1 expression/replication in JLTRG-R5 cells allows for the acquisition of additional data at the end of the drug screen by selectively collecting samples from interesting wells and subjecting them to flow cytometric analysis. By this means, data on, for example, cell viability, apoptosis, or activation markers can be immediately obtained. Because JLTRG-R5 cells are susceptible to infection with a wide variety of patient isolates, the cells can then be used for detailed verification analysis.
We obtained optimal readout after 96 h. This incubation period may, similar to other infectivity assays, impose a limitation with respect to the successful identification of highly instable but potentially inhibitory compounds. However, due to the relatively short half-life of the infectious viral particles in the inoculum, this should only affect the detection of extremely short-lived HIV-1 entry/ . EGFP fluorescence as a quantitative marker for HIV-1 expression was measured after 3 days using plate-based fluorometry. Infectious viral culture supernatants containing (A) HIV-1 BAL or (B) HIV-1 NL4-3 were pretreated for 1 h with various amounts of serum from five HIV-1 patients and one noninfected volunteer (0-10 μL). Patient sera KIMA, SMST, SHRO, and SPKE had been previously determined as highly neutralizing, whereas the patient serum YOAL has low reactivity. The serum COJA originates from a healthy volunteer. The serum-treated infectious supernatants were then added to the JLTRG-R5 cells that had been seeded at a density of 1 × 10 5 cells per 384-well plate (total volume 100 μL). The plates were analyzed for EGFP fluorescence 4 days postinfection. HIV-1, human immunodeficiency virus type 1; EGFP, enhanced green fluorescent protein.
RESEARCH REPORT fusion inhibitors. For other HIV-1 inhibitors (e.g., reverse transcriptase or protease inhibitors), compound stability has a greater influence on the sensitivity of the assay; however, the delay in viral replication that is caused by the initial presence of the unstable compound will still allow for the detection of a compound with a reasonably short half-life and would justify advancement to a drug development state. A second limitation that is generally shared among cell-based assays is imposed by the potential cytotoxicity of the carrier substance (e.g., DMSO), in which the compounds are dissolved. JLTRG-R5 cells tolerate a DMSO concentration of up to 0.5% DMSO. Higher DMSO concentrations activate the cells, which may adversely influence a drug screening effort. The tolerance of the cells with respect to the carrier substance defines the upper limit for the utilized compound concentration. In a situation where higher drug concentrations are desirable, molecular target screens are clearly preferable.
Notably, the IC 50 data for the HIV-1 reverse transcriptase inhibitor 3TC, the protease inhibitor indinavir, and the entry/fusion inhibitors TAK-779 and T-20 obtained in either experimental format compare very well with data previously obtained for these drugs (19, 21) . This ability of JLTRG-R5 cells to reproduce data previously obtained on PBMCs and the convenience of EGFP as a direct and quantitative readout for HIV-1 expression make JLTRG-R5 cells a very powerful and unique tool that should greatly enhance our ability to identify novel HIV-1 inhibitors.
